Approximately 50% of Asian lung cancer patients are EGFR-activating mutations, and the median progression-free survival of patients with EGFR-activating mutations using EGFR-TKI is 13 months, with a median survival of 23 months l31, 32. This evidence concerns the gene EGFR and lung carcinoma.